Interim Report April - September 2021
A strong quarter for both our pharma sales and our sales of Covid-19 tests July - September · Consolidated sales during the second quarter, July to September amounted to SEK 52.5 (24.2) million. Adjusted for non-recurring sales the revenue amounted to 34.5 (24.2) MSEK, an increase of 42.6%. · Gross profit amounted to SEK 16.3 (10.4) million for the quarter, an increase of 56.4%. · EBIT for the quarter was SEK 5.9 (3.4) million. · Earnings per share were SEK 0:18 (0:11) for the quarter. · Cash flow from operating activities amounted to SEK 4.3 (-40.0) million for the